Overview

Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation

Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Single-centre, open-label, randomized, two-sequence, two-way crossover study. The study consisted of two consecutive single-dose treatment periods separated by a washout period of 10 to 14 days or more.
Phase:
Phase 1
Details
Lead Sponsor:
Bial - Portela C S.A.
Treatments:
Opicapone